BD
Belay Diagnostics provides advanced genomic profiling tests, Summit™ and Vantage™, utilizing cerebrospinal fluid (CSF) for central nervous system malignancies. These liquid biopsy assays offer clinicians a validated and accurate alternative to invasive biopsies for diagnosis and treatment management. The company aims to support clinicians in achieving a higher standard of care for patients with primary and metastatic brain and spinal cord cancers.
Updated 4 months ago
Funding
$304K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
H
Founders
Founder details are not available yet.
Product
Features
- Belay Diagnostics provides advanced genomic profiling tests, Summit™ and Vantage™, utilizing cerebrospinal fluid (CSF) for central nervous system malignancies. These liquid biopsy assays offer clinicians a validated and accurate alternative to invasive biopsies for diagnosis and treatment management. The company aims to support clinicians in achieving a higher standard of care for patients with primary and metastatic brain and spinal cord cancers.